Document is current
Any future updates will be listed below
-
Authors
Haralambieva, Iana H.
Ovsyannikova, Inna G.
Kennedy, Richard B.
Larrabee, Beth R.
Zimmermann, Michael T.
Grill, Diane E.
Schaid, Daniel J.
Poland, Gregory A.
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (AI033144)
National Institute of Allergy and Infectious Diseases (AI048793)
- License Information
-
More Information
Article History
Received: 3 October 2016
Accepted: 14 February 2017
First Online: 13 March 2017
Compliance with ethical standards
:
: Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., CSL Biotherapies, Avianax, Dynavax, Novartis Vaccines and Therapeutics, Emergent Biosolutions, Adjuvance, Microdermis, Seqirus, NewLink, Protein Sciences, GSK Vaccines, and Sanofi Pasteur. Drs. Poland and Ovsyannikova hold three patents related to measles and vaccinia peptide research. Dr. Kennedy has received funding from Merck Research Laboratories to study waning immunity to measles and mumps after immunization with MMR-II®. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.
